The Pharmaceutical Industry is currently facing major challenges: greater complexity in producing NCEs (New Chemical Entities), intensified regulatory requirements, more patent expiration of top products, propagation of generic competition, increased cost of technology, drop in share value, and diminished confidence from both the public sector and Wall Street. These challenges and the pressure to reduce cycle time without compromising innovation result in substantially increased cost of Drug Discovery and Development. Many of these challenges are addressed through resourcefulness, process refinement and optimization, and enabling technologies including combinatorial chemistry, HTS, and structure-based design. To implement these and other technologies, there is a staggering requirement for more chemists, and not diminished need for capacity as originally perceived. Outsourcing, collaborations, and alliance partnerships can present a company with added flexibility and the chance to “stretch” the value of research dollars. The speaker will highlight these issues and provide his own assessment of the future outlook for chemistry.
Back to Enterprise 2015: Chemistry at the Crossroads of Science
Back to The 37th Middle Atlantic Regional Meeting (May 22-25, 2005)